Skip to main content

Advertisement

SpringerLink
Log in

Oxaliplatin plus gemcitabine as a salvage schedule for hormone-refractory prostate adenocarcinoma

  • Case Reports
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

We report a case of hormone-refractory prostate cancer (HRPC) treated with oxaliplatin plus gemcitabine in a third-line schedule after liver progression, with an excellent clinical, biochemical and radiological response and with an acceptable tolerance. Prior chemotherapy regimens included docetaxel plus estramustine and oral etoposide. To our knowledge, this is the first report that shows this approach in an HRPC patient.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Petrylak DP, Tangen CM, Hussain MH et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513–1152

    Article  PubMed  CAS  Google Scholar 

  2. Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512

    Article  PubMed  CAS  Google Scholar 

  3. Droz JP, Muracciole X, Mottet N et al (2003) Phase II study of oxaliplatin versus oxaliplatin combined with infusional 5-fluorouracil in hormone refractory metastatic prostate cancer patients. Ann Oncol 14:1291–1298

    Article  PubMed  CAS  Google Scholar 

  4. Di Lorenzo G, Autorino R, Giuliano M et al (2007) Phase II trial of gemcitabine, prednisone, and zoledronic acid in pretreated patients with hormone refractory prostate cancer. Urology 69:347–351

    Article  PubMed  Google Scholar 

  5. Qin ZK, Yang GW, Zhou FJ et al (2004) Short-term efficacy of combined chemotherapy of gemcitabine and cisplatin on advanced hormone refractory prostate cancer. Ai Zheng 23:1700–1703

    PubMed  Google Scholar 

  6. Inoue S, Oka K, Araki T et al (2007) Neuroendocrine carcinoma of the prostate effectively treated by cisplatin and irinotecan-a case report. Gan To Kagaku Ryoho 34:1323–1325

    PubMed  Google Scholar 

  7. Feinstein T, Appleman LJ, Friedland DM et al (2007) A phase II trial of oxaliplatin and docetaxel in patients with androgen independent prostate cancer (AIPC) who have progressed to two prior regimens of chemotherapy. J Clin Oncol, ASCO Annual Meeting Proceedings Part I 25(18S).

Download references

Author information

Authors and Affiliations

  1. Medical Oncology Department, Clínica Universitaria de Navarra, Avda. Pío XII, 36, ES-31008, Pamplona, Spain

    Marta Santisteban, José Luis Pérez-Gracia, Jaime Ceballos & Jesús García-Foncillas

  2. Radiology Department, Clínica Universitaria de Navarra, Pamplona, Spain

    Isabel Vivas

Authors
  1. Marta Santisteban
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. José Luis Pérez-Gracia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jaime Ceballos
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Isabel Vivas
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jesús García-Foncillas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marta Santisteban.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Santisteban, M., Pérez-Gracia, J.L., Ceballos, J. et al. Oxaliplatin plus gemcitabine as a salvage schedule for hormone-refractory prostate adenocarcinoma. Clin Transl Oncol 10, 372–374 (2008). https://doi.org/10.1007/s12094-008-0214-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-008-0214-9

Keywords

Search

Navigation